They also don’t directly support behavior change, which Kathryn Ilonka Pollak, PhD, a professor in population health sciences ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Researchers have discovered gut bacteria that may naturally suppress hunger, offering a potential alternative to drugs like ...

HOUSTON - Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotech company with a market capitalization of approximately $90 million, is expanding its investigational pipeline with the ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Analysis of drugs such as Ozempic finds a lower health risk for 42 conditions but a higher rate of disorders such as arthritis ...

Our research covers several areas including the study of islet endocrine cell physiology, identity and connectivity, biomarkers for type 2 diabetes, the role of nutrient regulated protein kinases, ...

If that person loses 20 kilograms (44 pounds) in one year while taking a GLP-1R agonist — which is not unreasonable while ...

molecular biology, and medicine, seeking novel and more effective drugs, which led to the approval of new hormones or their analogs for their therapeutic use in different countries. One example is the ...

Many examples of utilization of the biology of FcRn have given rise to new classes of ... neonatal Fc receptor; GLP-1, glucagon-like peptide-1; gp, glycoprotein; HC, heavy chain; HER2, human epidermal ...